Search

everythinglearnresearchcommunity

for

Search:↓

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

Febron Hair fiber quality has decreased since post-pandemic era, causing fibers to stick to fingers. Users seek better brand recommendations.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

A user has been experiencing hair loss for 4 years, with treatments like minoxidil, finasteride, and various supplements proving ineffective. They were diagnosed with fibrosing alopecia in a pattern distribution, a condition that may require a combination of anti-inflammatory and hair growth treatments.

The conversation discusses using GFM Gel, a topical gel with polypeptides that mimic growth factors to promote hair regrowth and strengthen hair. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

Keratin fusion bonds are discussed as an alternative to clip-on hair patches for men with diffused thinning. The conversation explores different styling options for hair loss.

Hair fibers effectively cover thin hair areas, boosting confidence and reducing stress about hair appearance. Users discuss combining hair fibers with other products like hair spray, dermmatch, and Boldify, noting challenges like blocking minoxidil absorption and the importance of color matching.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Low folic acid may worsen side effects of finasteride. Consult a doctor for personalized advice.

The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.

Follica's preferred microneedling protocol for hair growth, which includes needle depth, frequency and movement parameters as well as the use of topical treatments such as minoxidil and finasteride.

The conversation is about the potential risk of permanent hair loss from PRP (platelet rich plasma) treatments and whether PRF (platelet rich fibrin) carries the same risk. The user is seeking information on this topic.

A treatment containing Wnt and Follistatin was found to be safe and effective for hair regrowth in a Phase 1 clinical trial. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

The conversation discusses concerns about using hair fibers while microneedling, specifically the potential for clogging pores. It is suggested that microneedling should not cause bleeding.

The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.

Fluridil, also known as Topilutamide or Eucapil, is discussed as a treatment for hair loss. It is noted as an androgen receptor antagonist, not a vasodilator.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.